EQS-News

Relief Therapeutics Reports that its Collaboration Partner, NRx Pharmaceuticals, has Submitted an Application for Emergency Use Authorization for Aviptadil to the U.S. Food & Drug Administration

EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Miscellaneous Relief Therapeutics Reports that its Collaboration Partner, NRx Pharmaceuticals, has Submitted an Application for Emergency Use Authorization for Aviptadil to the U.S. Food & Drug Administration 02.06.2021 / 07:00 Relief Therapeutics Reports that its Collaboration Partner, NRx Pharmaceuticals, has Submitted an Application for Emergency Use Authorization for Aviptadil to the U.S. Food & Drug Administration

Geneva, Switzerland, June 2, 2021 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ("Relief"), a biopharmaceutical company with its lead compound RLF-100(TM) (aviptadil) in advanced clinical development to treat COVID-19-induced respiratory disorders, reported today that its collaboration partner, NRx Pharmaceuticals, Inc. (formerly known as: NeuroRx Pharmaceuticals, Inc.), has announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking Emergency Use Authorization (EUA) for the use of aviptadil in the treatment of critical COVID-19 in patients with respiratory failure. NRx's press release announcing its EUA submission can be accessed through the following link.

"We are delighted that our partner has submitted aviptadil for EUA and look forward to a decision by the Agency," said Raghuram (Ram) Selvaraju, Chairman of the Board of Relief. "Despite the increase in the number of people being fully vaccinated against COVID-19, with emerging variants and disparities in vaccination rates, there remains a major need for effective therapeutic options for patients with respiratory failure. We are excited about the potential aviptadil holds in helping critical COVID-19 patients and are hopeful that the drug candidate will soon be available to those who remain in need of better treatments."

Dr. Selvaraju continued: "We would also like to take this opportunity to not only congratulate our partner on completing the EUA submission but also on their recent listing on Nasdaq."

The EUA submission is based on the results of a COVID-19 IV randomized, placebo-controlled phase 2b/3 clinical trial conducted by NRx in the United States. Relief also confirms that it has received a copy of the clinical study report from this trial from NRx and looks forward to pursuing the best path forward for the development of IV RLF-100 in Europe and other territories.